Defining response and non-response to treatment in patients with overactive bladder: a systematic review

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Irwin DE, Abrams P, Milsom I, et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 2008;101:1381-7
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, et al. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 2008;53:1029-37
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
   PubMed Web of Science ®Google Scholar
• Franco I. Pediatric overactive bladder syndrome: pathophysiology and management. Paediatr Drugs 2007;9:379-90
   PubMedGoogle Scholar
• Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 2009;63:1177-91
   PubMed Web of Science ®Google Scholar
• Rosenberg MT, Dmochowski RR. Overactive bladder: evaluation and management in primary care. Cleve Clin J Med 2005;72:149-56
   PubMed Web of Science ®Google Scholar
• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rosenberg MT, Brenes FJ. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 2009;104:960-7
   PubMed Web of Science ®Google Scholar
• Klutke CG, Burgio KL, Wyman JF, et al. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol 2009;181:2599-607
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L. Overactive bladder: diagnosis and management. Maturitas 2012;71:188-93
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Herschorn S, Carlsson M, et al. Urgency urinary incontinence response rates in subjects with overactive bladder treated with fesoterodine 8 mg after suboptimal response to tolterodine extended release 4 mg: a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn 2013;32:S1-S58
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase iii, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-32
   PubMed Web of Science ®Google Scholar
• Urinary Incontinence Treatment Network. Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study. Contemp Clin Trials 2007;28:48-58
   PubMed Web of Science ®Google Scholar
• Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007;23:2347-58
   PubMed Web of Science ®Google Scholar
• Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
   PubMedGoogle Scholar
• Colman S, Chapple C, Nitti V, et al. Validation of Treatment Benefit Scale for assessing subjective outcomes in treatment of overactive bladder. Urology 2008;72:803-7
   PubMed Web of Science ®Google Scholar
• Sussman DO, Kraus SR, Carlsson M, et al. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007;23:777-81
   PubMed Web of Science ®Google Scholar
• Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 2005;21:71-80
   PubMed Web of Science ®Google Scholar
• Bolduc S, Moore K, Lebel S, et al. Double anticholinergic therapy for refractory overactive bladder. J Urol 2009;182:2033-8
   PubMed Web of Science ®Google Scholar
• van der Pal F, van Balken MR, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU Int 2006;97:547-50
   PubMed Web of Science ®Google Scholar
• Khan S, Panicker J, Roosen A, et al. Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks. Eur Urol 2010;57:891-6
   PubMed Web of Science ®Google Scholar
• Denys P, Le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012;61:520-9
   PubMed Web of Science ®Google Scholar
• Hoebeke P, De Caestecker K, Vande Walle J, et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 2006;176:328-30, discussion 30-1
   PubMed Web of Science ®Google Scholar
• Lahdes-Vasama TT, Anttila A, Wahl E, et al. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Scand J Urol Nephrol 2011;45:397-400
   PubMed Web of Science ®Google Scholar
• Okamura K, Nojiri Y, Ameda K, et al. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes. Int J Urol 2011;18:483-7
   PubMed Web of Science ®Google Scholar
• Alloussi SH, Lang C, Eichel R, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. World J Urol 2012;30:367-73
   PubMed Web of Science ®Google Scholar
• Finazzi Agro E, Campagna A, Sciobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva Urol Nefrol 2005;57:119-23
   PubMedGoogle Scholar
• Finazzi Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010;184:2001-6
   PubMed Web of Science ®Google Scholar
• Yoong W, Ridout AE, Damodaram M, et al. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int 2010;106:1673-6
   PubMed Web of Science ®Google Scholar
• South MM, Romero AA, Jamison MG, et al. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:1395-8
   PubMed Web of Science ®Google Scholar
• Lordelo P, Soares PV, Maciel I, et al. Prospective study of transcutaneous parasacral electrical stimulation for overactive bladder in children: long-term results. J Urol 2009;182:2900-4
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Malone DC, Bui CN. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. J Med Econ 2012;15(Suppl 1):35-44
   PubMedGoogle Scholar
• Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006;26:1694-702
   PubMed Web of Science ®Google Scholar
• Arlandis-Guzman S, Errando-Smet C, Trocio J, et al. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urol 2011;11:9
   PubMed Web of Science ®Google Scholar
• Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006;50:1050-7
   PubMed Web of Science ®Google Scholar
• McDowell DT, Noone D, Tareen F, et al. Urinary incontinence in children: botulinum toxin is a safe and effective treatment option. Pediatr Surg Int 2012;28:315-20
   PubMed Web of Science ®Google Scholar
• Burgio KL, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008;149:161-9
   PubMed Web of Science ®Google Scholar
• Payne CK, Kelleher C. Redefining response in overactive bladder syndrome. BJU Int 2007;99:101-6
   PubMed Web of Science ®Google Scholar
• Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers. Eur Urol 2009;56:534-43
   PubMed Web of Science ®Google Scholar
• Chapple CR, Herschorn S, Abrams P, et al. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration. BJU Int 2010;106:1332-8
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Gong J, et al. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int 2012;109:1831-40
   PubMed Web of Science ®Google Scholar
• Zinner N, Noe L, Rasouliyan L, et al. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. Am J Geriatr Pharmacother 2009;7:373-82
   PubMed Web of Science ®Google Scholar
• Marcelissen TA, Leong RK, de Bie RA, et al. Long-term results of sacral neuromodulation with the tined lead procedure. J Urol 2010;184:1997-2000
   PubMed Web of Science ®Google Scholar
• Marcelissen TA, Leong RK, Serroyen J, et al. The use of bilateral sacral nerve stimulation in patients with loss of unilateral treatment efficacy. J Urol 2011;185:976-80
   PubMed Web of Science ®Google Scholar
• Marcelissen T, Leong R, Serroyen J, et al. Is the screening method of sacral neuromodulation a prognostic factor for long-term success? J Urol 2011;185:583-7
   PubMed Web of Science ®Google Scholar
• Leong RK, De Wachter SG, Nieman FH, et al. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. Neurourol Urodyn 2011;30:1249-52
   PubMed Web of Science ®Google Scholar
• Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 2008;101:325-9
   PubMed Web of Science ®Google Scholar
• Groenendijk PM, Heesakkers JP, Lycklama ANAA. Urethral instability and sacral nerve stimulation – a better parameter to predict efficacy? J Urol 2007;178:568-72, discussion 72
   PubMed Web of Science ®Google Scholar
• Van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 2007;99:107-10
   PubMed Web of Science ®Google Scholar
• White WM, Mobley JD 3rd, Doggweiler R, et al. Sacral nerve stimulation for refractory overactive bladder in the elderly population. J Urol 2009;182:1449-52
   PubMed Web of Science ®Google Scholar
• Groenendijk PM, Halilovic M, Chandi DD, et al. Extracorporeal magnetic innervation therapy: assessment of clinical efficacy in relation to urodynamic parameters. Scand J Urol Nephrol 2008;42:433-6
   PubMed Web of Science ®Google Scholar
• van Balken MR, Vergunst H, Bemelmans BL. Prognostic factors for successful percutaneous tibial nerve stimulation. Eur Urol 2006;49:360-5
   PubMed Web of Science ®Google Scholar
• Kantartzis K, Shepherd J. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder. Curr Opin Obstet Gynecol 2012;24:331-6
   PubMed Web of Science ®Google Scholar
• Onal M, Ugurlucan FG, Yalcin O. The effects of posterior tibial nerve stimulation on refractory overactive bladder syndrome and bladder circulation. Arch Gynecol Obstet 2012;286:1453-7
   PubMed Web of Science ®Google Scholar
• Karademir K, Baykal K, Sen B, et al. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. Scand J Urol Nephrol 2005;39:230-3
   PubMed Web of Science ®Google Scholar
• Marchal C, Herrera B, Antuna F, et al. Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started? Urology 2011;78:1046-50
   PubMed Web of Science ®Google Scholar
• Marte A, Borrelli M, Sabatino MD, et al. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur J Pediatr Surg 2010;20:153-7
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22
   PubMed Web of Science ®Google Scholar
• Okamura K, Hasegawa T, Nojiri Y, et al. Diagnosis and treatment of lower urinary tract symptoms in the elderly by general practitioners. Geriatr Gerontol Int 2008;8:119-25
   PubMed Web of Science ®Google Scholar
• Yoo EH, Kim YM, Kim D. Factors predicting the response to biofeedback-assisted pelvic floor muscle training for urinary incontinence. Int J Gynaecol Obstet 2011;112:179-81
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 2013;61:185-93
   PubMed Web of Science ®Google Scholar
• Liu HT, Kuo HC. Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. BJU Int 2007;100:1086-90
   PubMed Web of Science ®Google Scholar
• Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007;178:1359-63
   PubMed Web of Science ®Google Scholar
• Wyman JF, Klutke C, Burgio K, et al. Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. Can J Urol 2010;17:5283-90
   PubMed Web of Science ®Google Scholar
• Wyman JF, Harding G, Klutke C, et al. Contributors to satisfaction with combined drug and behavioral therapy for overactive bladder in subjects dissatisfied with prior drug treatment. J Wound Ostomy Continence Nurs 2010;37:199-205
   PubMed Web of Science ®Google Scholar
• Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009;63:560-7
   PubMed Web of Science ®Google Scholar
• Zinner N, Kobashi KC, Ebinger U, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 2008;62:1664-74
   PubMed Web of Science ®Google Scholar
• Goldman HB, Morrow JD, Gong J, et al. Early onset of fesoterodine efficacy in subjects with overactive bladder. BJU Int 2011;107:598-602
   PubMed Web of Science ®Google Scholar
• Piault E, Evans CJ, Espindle D, et al. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 2008;27:179-90
   PubMed Web of Science ®Google Scholar
• Aaron LE, Morris TJ, Jahshan P, Reiz JL. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Curr Med Res Opin 2012;28:1369-79
   PubMed Web of Science ®Google Scholar
• Pleil AM, Coyne KS, Reese PR, et al. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue – the BSW. Value Health 2005;8:S25-34
   PubMed Web of Science ®Google Scholar
• Choo MS, Doo CK, Lee KS. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract 2008;62:191-6
   PubMed Web of Science ®Google Scholar
• Lee KS, Lee YS, Kim JC, et al. Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms. Int J Clin Pract 2012;66:663-70
   PubMed Web of Science ®Google Scholar
• Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
   PubMed Web of Science ®Google Scholar
• Herschorn S, Jones JS, Oelke M, et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology 2010;75:1149-55
   PubMed Web of Science ®Google Scholar
• Kraus SR, Ruiz-Cerdá JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010;76:1350-7
   PubMed Web of Science ®Google Scholar
• Sand PK, Morrow JD, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:827-35
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Juenemann K, et al. Comparison of fesoterodine and tolterodine in subjects with overactive bladder. BJU Int 2008;102:1128-32
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008;102:56-61
   PubMed Web of Science ®Google Scholar
• Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, MacDiarmid SA, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn 2013;32:24-9
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Wooldridge LS, et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol 2013;189:2194-201
   PubMed Web of Science ®Google Scholar
• Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62:507-14
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010;58:919-26
   PubMed Web of Science ®Google Scholar
• Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98-101
   PubMed Web of Science ®Google Scholar
• Tincello DG, Owen RK, Slack MC, et al. Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study. BJOG 2013;120:212-16
   PubMed Web of Science ®Google Scholar
• Lordelo P, Teles A, Veiga ML, et al. Transcutaneous electrical nerve stimulation in children with overactive bladder: a randomized clinical trial. J Urol 2010;184:683-9
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
   PubMed Web of Science ®Google Scholar
• Kuo HC. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity. Neurourol Urodyn 2011;30:1497-502
   PubMed Web of Science ®Google Scholar
• Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2011;30:1242-8
   PubMed Web of Science ®Google Scholar
• Cardozo L, Coyne KS, Versi E. Validation of the Urgency Perception Scale. BJU Int 2005;95:591-6
   PubMed Web of Science ®Google Scholar
• Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006;60:745-51
   PubMed Web of Science ®Google Scholar
• Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171:752-6
   PubMed Web of Science ®Google Scholar
• Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. Int J Clin Pract 2009;63:973-6
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188:2455-63
   PubMed Web of Science ®Google Scholar
• Nitti VW, Kopp Z, Lin AT, et al. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion. Neurourol Urodyn 2010;29:652-7
   PubMed Web of Science ®Google Scholar
• Herschorn S, Kaplan SA, Wang JT, et al. Can baseline characteristics of subjects with overactive bladder predict responsiveness to antimuscarinic treatment. European Association of Urology, 24–28 February 2012, Paris, France
   Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
   PubMed Web of Science ®Google Scholar
• Michel MC, Chapple CR. Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol 2009;56:298-307
   PubMed Web of Science ®Google Scholar
• Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005;95:335-40
   PubMed Web of Science ®Google Scholar
• Blaivas JG, Panagopoulos G, Weiss JP, et al. Two types of urgency. Neurourol Urodyn 2009;28:188-90
   PubMed Web of Science ®Google Scholar
• Abrams P, Chapple CR, Junemann KP, et al. Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. World J Urol 2012;30:385-92
   PubMed Web of Science ®Google Scholar
• Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604-7
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006;97:96-100
   PubMed Web of Science ®Google Scholar
• Subak LL, Brown JS, Kraus SR, et al. The ‘costs’ of urinary incontinence for women. Obstet Gynecol 2006;107:908-16
   PubMed Web of Science ®Google Scholar
• Campbell JD, Gries KS, Watanabe JH, et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol 2009;9:18
   PubMedGoogle Scholar
• Coyne KS, Tubaro A, Brubaker L, et al. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006;68:9-16
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 2007;23:65-76
   PubMed Web of Science ®Google Scholar
• Smith AL, Nissim HA, Le TX, et al. Misconceptions and miscommunication among aging women with overactive bladder symptoms. Urology 2011;77:55-9
   PubMed Web of Science ®Google Scholar
• Brubaker L, Khullar V, Piault E, et al. Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J 2011;22:937-46
   PubMed Web of Science ®Google Scholar
• Brubaker L, Piault EC, Tully SE, et al. Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms. Int J Clin Pract 2013;67:342-50
   PubMed Web of Science ®Google Scholar
• Khullar V, Espuna-Pons M, Marschall-Kehrel D, et al. Clinical value of a patient-reported goal-attainment measure: the global development of Self-Assessment Goal Achievement (SAGA) questionnaire for patients with lower urinary tract symptoms. Neurourol Urodyn 2013. Epub ahead of print
   Web of Science ®Google Scholar